NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 9 of 24
Melatonin Use After Primary Total Joint Arthroplasty
NCT04795336
Increasing Patient Experience Survey Responses
NCT04994366
PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease
NCT05031520
Nudging Provider Adoption of Clinical Decision Support
NCT05203185
A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI
NCT04818593
Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS
NCT04218708
Use of the Napoleon to Improve Polyp Measurement in Gastroenterology Fellows
NCT04858477
Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy
NCT04831736
Family Intervention for Chinese Americans With Type 2 Diabetes
NCT04108299
Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)
NCT04843774
Couples Lived Experience
NCT04863495
Progressive Tension Sutures in Gender Affirming Mastectomy
NCT04818580
Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
NCT04814433
Registry of Thiola EC Therapy
NCT05048563
A Mobile Health Intervention to Reduce Diabetes Disparities in Chinese Americans
NCT03557697
Evaluating the Impact of Reining in Anxiety
NCT04825756
The Effect of Mindfulness Programs on Postoperative Pain
NCT04788329
Pediatric Vaccinations
NCT04936776
Improving Gap Closure Rates Using a Predictive Model
NCT04806984
Evaluation of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program
NCT04773834
Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid
NCT04786210
Comparison of Office-based KTP and CO2 Laser Outcomes in Patients With Vocal Cord Lesions.
NCT04575142
Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
NCT04219540
TXA in Revision Total Shoulder Arthroplasty
NCT04650698
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
NCT04682548
Cold Milk for Dysphagia in Preterm Infants
NCT04421482
Geniculate Artery Embolization for Treatment of Osteoarthritis
NCT04379700
A Randomized Trial of a BE-EHR Module to Guide the Care of Older Adults With Diabetes
NCT04181307
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
NCT04672252
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection
NCT04126278
Planned Semi-Elective Lung Transplantation Using 10C Cold Static Preservation
NCT04568694
Emergency Department Outcomes for Patients With Opioid Use Disorder
NCT04289363
Impacts of a Physician-targeted Price Transparency Tool on Medication Out-of-pocket Costs
NCT04940988
Telerehabilitation Following Meniscectomy
NCT04644640
Electronic Cigarettes as a Harm Reduction Strategy Among Patients With COPD
NCT04465318
Effectiveness of Nerve Glide Exercises on Cubital Tunnel Syndrome
NCT03629470
Buprenorphine Loading in the Emergency Department
NCT04283500
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder
NCT04063267
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
NCT04855617
Envarsus XR in Lung Transplant
NCT04420195
Providing Personalized Health and Individual Lifestyle Enhancing Solutions (Prophiles) in CVD
NCT03643146
PREDHICT: Precision Recruitment and Engagement of Diabetics and Hypertensives in Clinical Studies
NCT04286113
Wrist Arthroscopy Study
NCT04457362
Take the Pressure Off, NYC!
NCT04666909
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
NCT04317053
TXA in Anticoagulated Patients Study
NCT04560010
Integrating the Quit and Stay Quit Monday Model Into Smoking Cessation Services for Smokers With Mental Health Conditions
NCT04512248
TeleRehabilitation Following ACL Reconstruction
NCT04541940
A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT
NCT04509765
Computer Aided Detection, Tandem Colonoscopy Study
NCT04074577
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.